Abstract :

In this study, an analysis of the incidence of COVID–19 in the Fergana region was carried out, the number of vaccinated vaccination coverage and those who recovered after vaccination with COVID–19 was determined. The incidence was studied for the period from March 2020 to 2022. Since vaccination began in 2021, we analyzed those vaccinated and recovered from 2021 to 2022. The dynamics of the incidence of COVID–19 in the Fergana region was undulating. During the surveyed period, the intensive indicator of the incidence of COVID–19 was as follows: in the city of Fergana (887.6), Kuvasay–1169.5, Kuva–995, Sokh–737.2, Yazyavan–781, Altiarik–610.1, Fergana–472 cases per 100,000 populations. During this period, more than 7 million doses of COVID–19 vaccines were administered, and no side effects of the vaccines used were observed among those vaccinated.

---

Keywords :

coronavirus infection, COVID-19, epidemiological analysis., Fergana region, Immunization, Infectious Diseases, medical knowledge, primary medical care, psychological knowledge, results, Vaccination., World Health Organization

---

References :

1. Baden L.R., Sahly H.M., Essink B., et al. Efficacy and safety of the mRNA–1273 SARS–CoV–2 vaccine. // N Engl J Med. – Vol. 384, 2021. – p. 403–416.
2. Blumenthal K.G., Freeman E.E., Saff R.R., et al. Delayed Large Local Reactions to mRNA–1273 Vac–cine against SARS–CoV–2 // N Engl J Med. – Vol. 384, 2021. ‒ p. 1273–1277.
3. COVID–19: Human rights principles must guide health decisions. https://www.coe.i nt/en/web/bioethics/-/covid-19-human-rights-principles-must-guidehealth-decisio-1 (accessed 16.01.2022).
4. Castells M.C., Phillips E.J. Maintaining Safety with SARS–CoV–2 Vaccines // N Engl J Med. – Vol. 384, № 7, 2021. – p. 643–649.
5. Choi K.W., Chau T.N., Tsang O. et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med., 139(9), 2003. – p. 715–723.
6. Chen T., Wu D., Chen H. et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020. – p. 368.
7. Cines D.B., Bussel J.B. SARS–CoV–2 Vaccine–Induced Immune Thrombotic Thrombocytopenia. Published: Online, April 16, 2021.
8. D’Souza R. et al. Pregnancy and COVID–19: Pharmacologic considerations. Ultrasound Obstet Gynecol. 2021, February, 57(2). – p. 195–203.
9. Diriba K., Awulachew E., Getu E. The effect of coronavirus infection (SARS–CoV–2, MERS–CoV, and SARS–CoV) during pregnancy and the possibility of vertical maternal–fetal transmission: a systematic review and meta–analysis. Eur J Med Res. 2020 Sep 4; 25(1):39.
10. Judit S. Bioethics for the Pandemic. https://www.project-syndicate.org/commentar y/bioethics-principles-for-COVID-19-response-by-judit-sandor-2020-05 (accessed 16. 01.2022).
11. Spasennikov B.A. COVID–19 pandemic: some lessons. Bulletin of Semashko National Research Institute of Public. Health, 2020, No. 4. – p. 52–57.
12. Huang Y., Tu M., Wang S. et al. Clinical characteristics of laboratory confirmed positive cases of SARS–CoV–2 infection in Wuhan, China: a retrospective single center analysis. Travel Med Infect Dis. 2020.
13. Parazzini F., Bortolus R., Mauri P.A., Favilli, A., Gerli, S., Ferrazzi, E. (2020). Delivery in pregnant women infected with SARS CoV 2: A fast review. International Journal of Gynecology & Obstetrics.
14. Saad A.F., Chappell L., Saade G.R. et al. Corticosteroids in the Management of Pregnant Patients with Coronavirus Disease (COVID–19). Obstet Gynecol 2020, 136. – p. 823–82
15. Liu T., Zhang J., Yang Y. et al. The potential role of IL–6 in monitoring severe case of coronavirus disease 2019. MedRiv. 2020.
16. Ruan Q., Yang K., Wang W. Clinical predictors of mortality due to COVID–19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020, 46(5). – p. 846–848.
17. Wang S., Lin D., Yang X. et al. Prognostic value of C–reactive protein in patients with COVID–19. Infect Dis. 2020, 9. – p. 2445–2453.
18. World Health Organization. Clinical management of severe acute respiratory infection when COVID–19 is suspected. 13 March 2020. Five Privacy and Ethical Use Principles for Your COVID–19 Response.
19. World Health Organization. National Strategic Plan for Health Preparedness and Response, 2020. – p. 33.